Ambit will not seek accelerated approval for quizartinib based on Phase 2 data


Ambit Biosciences (AMBI) will not submit an NDA for accelerated approval of
quizartinib based on Phase 2 and Phase 2b data as the FDA does not agree that CR with incomplete hematologic recovery "represents a surrogate endpoint reasonably likely to predict clinical benefit."

After getting feedback from the regulator, the company still plans to "conduct a randomized, controlled Phase 3 clinical trial in relapsed/refractory FLT3-ITD positive AML patients."

OS will be the endpoint.

The company says it "remains committed to moving quizartinib through its late stage development as expeditiously as possible." (PR)

Shares are halted.

Comments (1)
  • toosmarttofail
    , contributor
    Comments (699) | Send Message
     
    The FDA sure doesn't like new drugs these days, just as Big Pharma stocks are at all-time highs.
    5 Dec 2013, 12:22 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs